Boston Scientific outlines its strategic approach to counteract expected market share erosion in the PFA and EP markets in 2026, emphasizing product innovation, increased commercial investment, and pipeline expansion.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
How is Boston Scientific addressing the market share erosion in PFA and EP markets in 2026?
Boston Scientific’s core message in its 2026 outlook is that it expects more competition-driven share erosion in its PFA (FARAPULSE/FARAPOINT catheter ecosystem) and EP markets in 2026, but believes it can retain PFA leadership by leaning on product pipeline, platform expansion (mapping/catheters), and targeted commercial investment.
Management acknowledges that competitive dynamics are causing share pressure and that the company is guiding accordingly: it “expect[s] a little bit more share erosion than… anticipated” while still aiming to maintain PFA market leadership in the U.S., internationally, globally in ’26 and throughout the LRP. 1
This is reinforced elsewhere in the call: the company says it is “guiding globally to approximate 10% [NEP]” and explains that even though it anticipated greater erosion, “we didn’t lose a bit more share than we anticipated,” while still being “the market share leader in PFA.” 2
Boston Scientific frames the environment as meaningfully more competitive, listing multiple large competitors active in PFA/EP:
In Europe, management also says it expects to keep growing at a “20%+ clip” due to its mapping/platform capability, even though it still anticipates some incremental erosion. 1
A major part of the defense strategy is increasing the strength and sophistication of its mapping footprint, which is intended to sustain share despite competitive entry.
Management says its “makers… continue to get stronger” each quarter, including:
This is also tied directly to EP growth performance: it reports that international EP growth is driven by “expanded OPAL Mapping footprint in catheter utilization” and “strong double-digit PFA growth in Europe in a highly competitive environment supported by the launch of FARAPOINT.” 4
Boston Scientific indicates it is increasing investment to support its EP franchises and to counter erosion—explicitly calling out WATCHMAN (a major part of the broader EP market activity) but also stating investments apply to EP and WATCHMAN commercial capabilities:
While the question is about PFA and EP share erosion, the transcript’s emphasis suggests the company is using EP “attention” and commercial muscle where procedure demand is shifting (concomitant vs standalone), which affects the overall EP/PFA competitive dynamics. 6
Management’s confidence is partly based on the next wave of PFA platform launches. It says there are “three big ones coming up” spanning into 2027 and the “next 2.5 years,” including:
Separately, it notes FANAFLEX development timing: “initiate… IDE later this year” and expects “launching FANAFLEX in the U.S. in 2028.” 7
Even with 2026 share pressure, this pipeline messaging is used to support the claim that leadership can be maintained while the platform advances. 17
Boston Scientific’s EP outlook suggests it expects continued EP growth even while accepting some share erosion:
In 2026, Boston Scientific is addressing expected PFA/EP market share erosion primarily through a combination of:
All of this supports the company’s 2026 thesis: accept some share pressure in the near term, but use installed base + commercialization + product evolution to maintain leadership in PFA while EP continues to grow. 134
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Boston Scientific outlines its comprehensive approach to managing increased competition and market share erosion in the PFA and EP markets for 2026, emphasizing product innovation, targeted marketing, and strategic execution.
Sources used
Research questionHow is Boston Scientific addressing the market share erosion in PFA and EP markets in 2026?
Answer outline
Boston Scientific is proactively managing increased competition in the PFA and EP markets by investing in platform development, expanding its ecosystem, and emphasizing product innovation to sustain leadership in 2026.
Sources used
Research questionHow is Boston Scientific addressing the market share erosion in PFA and EP markets in 2026?
Answer outline
Boston Scientific plans to address market share erosion in PFA and EP markets in 2026 through strategic investments, product innovation, and targeted marketing efforts amid intensified competition.
Sources used
Research questionHow is Boston Scientific addressing the market share erosion in PFA and EP markets in 2026?
Answer outline
Boston Scientific outlines its strategic approach to mitigating market share erosion in PFA and EP markets for 2026, emphasizing increased investment in platforms, commercialization, and ecosystem expansion to sustain leadership.
Sources used
Research questionHow is Boston Scientific addressing the market share erosion in PFA and EP markets in 2026?
Answer outline
Boston Scientific’s Q2 2026 commentary centers on a WAMGR target of roughly 7%–8% with no change to 2027 guidance, despite WATCHMAN headwinds. In Urology, near-term results are flat to modestly positive, with three core stone launches and Sacral Neuromodulation recovery expected to lift performance toward market rates in 2027.
Sources used
Research questionWhat did management say about WAMGR outlook and Urology launches?
Answer outline
Boston Scientific's updated 2026 guidance highlights meaningful revisions to WATCHMAN and EP, with management assuming ongoing market headwinds into 2027. The narrative frames EP improvement in 2H27 and a conservative WATCHMAN trajectory, signaling only modest 2027 organic growth and no immediate rebound unless market conditions shift, despite ongoing roadmap initiatives. The discussion also underscores a timeline where EP improves in 2027's second half and 2028 prospects strengthen with new technology launches, while WATCHMAN remains a challenge without a market change.
Sources used
Research questionPlease walk through the updated 2026 guidance, specifically the EP and WATCHMAN revisions, and what this implies for 2027 organic growth given current market trends?
Answer outline
Boston Scientific has revised its 2026 revenue and EPS guidance due to specific headwinds in its EP, WATCHMAN, and Urology segments, reflecting industry-wide challenges and competitive pressures.
Sources used
Research questionWhat are the reasons behind Boston Scientific's revision of its 2026 revenue and EPS guidance due to headwinds in EP WATCHMAN Urology?
Answer outline
Boston Scientific has lowered its 2026 revenue and EPS guidance due to headwinds in key segments, including Watchman, Urology, and Electrophysiology, reflecting changing market dynamics and competitive pressures.
Sources used
Research questionWhat are the reasons behind Boston Scientific's revision of its 2026 revenue and EPS guidance due to headwinds in EP WATCHMAN Urology?
Answer outline
Boston Scientific revised its 2026 revenue and EPS guidance due to emerging headwinds in its Urology and EP markets, driven by competitive pressures, procedure shifts, and product underperformance.
Sources used
Research questionWhat are the reasons behind Boston Scientific's revision of its 2026 revenue and EPS guidance due to headwinds in EP WATCHMAN Urology?
Answer outline
Boston Scientific has revised its 2026 revenue and EPS guidance driven by headwinds in the EP, WATCHMAN, and Urology sectors, reflecting unforeseen competitive and operational challenges.
Sources used
Research questionWhat are the reasons behind Boston Scientific's revision of its 2026 revenue and EPS guidance due to headwinds in EP WATCHMAN Urology?
Answer outline
Boston Scientific revised its 2026 revenue and EPS guidance primarily due to headwinds in the WATCHMAN, EP, and Urology sectors, reflecting changing market dynamics and competitive pressures.
Sources used
Research questionWhat are the reasons behind Boston Scientific's revision of its 2026 revenue and EPS guidance due to headwinds in EP WATCHMAN Urology?
Answer outline
U.S. Bancorp expects credit cards and commercial and industrial lending to be leading areas of loan growth, with commercial real estate also in the mix. As these relationship-oriented categories expand, residential mortgages could decline from about 30% to the mid-20% range of the portfolio—not because the bank plans to shrink the mortgage book, but because other lending grows faster.
Sources used
Research questionOver time, how should investors expect the loan portfolio mix to evolve, and which loan categories are most attractive for growth?
Answer outline
Dafinchi